« Back
Home /
hVEGF-IN-1

hVEGF-IN-1

Manufacturer	MedChem Express
Category	Oncology By Cell Type Carcinoma Cell Biology Cell Culture Cytokines Adenocarcinoma Inhibitors & Compound Libraries Small Molecules By Organ Bladder Cancer Colorectal Cancer
Type	Inhibitors
Specific against	other
Amount	1 mg
Item no.	HY-101931-1mg
Targets	VEGFR
CASRN	1637443-98-1
eClass 6.1	30220300
eClass 9.0	32160605
Available
Product Description	hVEGF-IN-1, a quinazoline derivative, could specifically bind to the G-rich sequence in the internal ribosome entry site A (IRES-A) and destabilize the G-quadruplex structure. hVEGF-IN-1 binds to the IRES-A (WT) with a Kd of 0.928 μM in SPR experiments. hVEGF-IN-1 could hinder tumor cells migration and repress tumor growth by decreasing VEGF-A protein expression[1].
StorageTemperature	-20°C, 3 years; 4°C, 2 years (Powder)
Shipping	Room Temperature
Manufacturers Applications	Cancer-Kinase/protease
MolecularWeight	581.75
Clinical_Information	No Development Reported
Manufacturers Research_Area	Cancer
Solubility	DMSO : 25 mg/mL (ultrasonic)
Manufacturers Target	VEGFR
Pathway	Protein Tyrosine Kinase/RTK
Manufacturers Product type	Reference compound

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-101931-1mg-safety-datasheet.pdf